人福医药集团股份公司 章 程 （草案） 二〇二五年七月 | . œ . | | --- | | V 1 | | 第一章 | 总则 | 2 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 3 | | | 第三章 | 股份 | 3 | | 第一节 | 股份发行 | 3 | | 第二节 | 股份增减和回购 4 | | | 第三节 | 股份转让 | 5 | | 第四章 | 股东和股东会 6 | | | 第一节 | 股东的一般规定 6 | | | 第二节 | 控股股东和实际控制人 8 | | | 第三节 | 股东会的一般规定 9 | | | 第四节 | 股东会的召集 12 | | | 第五节 | 股东会的提案与通知 14 | | | 第六节 | 股东会的召开 15 | | | 第七节 | 股东会的表决和决议 17 | | | 第五章 | 党委 | 21 | | 第六章 | 董事和董事会 21 | | | 第一节 | 董事 | 22 | | 第二节 | 董事会 | 24 | | 第三节 | 独立董事 28 | | | 第四节 | 董事会专门委员会 31 | | | 第七章 | 高级管理人员 3 ...

人福医药集团股份公司董事会议事规则 （2025年7月修订） 第一章 一般规定 第一条 为了进一步完善人福医药集团股份公司（以下简称"公司"）法人治理 结构，保障董事会依法独立、规范、有效地行使职权，以确保董事会的工作效率和科 学决策，根据《中华人民共和国公司法》(以下简称"《公司法》")《上市公司治理 准则》《上市公司章程指引》《上海证券交易所股票上市规则》（以下简称"《上市 规则》"）等相关法律、法规以及《人福医药集团股份公司章程》 (以下简称"《公 司章程》")的规定，制定本议事规则。 第二条 公司依法设立董事会。董事会是公司的经营决策机构，依据《公司法》等 相关法律、法规和《公司章程》的规定，对公司股东会负责。 第四条 董事由股东会选举或更换，并可在任期届满前由股东会解除其职务，每 届任期为三年。董事任期届满，可连选连任。 第五条 董事会根据《公司章程》下设战略委员会、审计委员会、提名委员会、薪 酬与考核委员会等专门委员会。专门委员会对董事会负责，依照《公司章程》和董事 会授权履行职责，提案应当提交董事会审议决定。 董事会专门委员会是董事会下设的专门工作机构，为董事会重大决策提供咨询、 建议。专门委员会 ...

Core Viewpoint - This week, 10 listed companies announced share buybacks and increases in shareholdings, with notable mention of Three Gorges Energy's controlling shareholder receiving a loan commitment of up to 2.7 billion yuan specifically for increasing its stake in the company [1][2]. Group 1: Companies Announcing Buybacks or Increases - Chongqing Pharmaceutical Holdings plans to repurchase shares worth 80 million to 100 million yuan, with a loan not exceeding 90 million yuan [2]. - Antong Holdings intends to increase its shareholding by 360 million to 720 million yuan [2]. - Renfu Pharmaceutical's shareholder received a loan commitment of 750 million yuan [2]. - ST Kelly's shareholder plans to increase its stake by no less than 14.39 million shares [2]. - Trina Solar has obtained a special loan commitment for stock repurchase [2]. - Suobede plans to repurchase shares worth 20 million to 30 million yuan for cancellation [2]. - Yanpai Co.'s controlling shareholder's concerted actor intends to increase holdings by 17 million to 34 million yuan [2]. - Hisense Home Appliances plans to continue increasing its holdings by 6.93 million to 13.86 million shares [2]. - Three Gorges Energy's controlling shareholder received a loan commitment of 2.7 billion yuan for shareholding increase [2]. - Xishan Technology's controlling shareholder plans to increase holdings by no less than 5 million yuan and no more than 10 million yuan [2].

Group 1 - Seli Medical's therapeutic hypertension vaccine project faces significant uncertainty despite recent market interest, with a 2024 revenue of 26,800 yuan and a net loss of 2,382,300 yuan [3] - Renfu Pharmaceutical's shareholder plans to increase their stake with a loan commitment of up to 750 million yuan, aiming to acquire 1% to 2% of the company's shares at a maximum price of 25.53 yuan per share [4] - China Northern Rare Earth's third-quarter trading price for rare earth concentrate is set at 19,109 yuan per ton, with price adjustments based on REO percentage changes [7][9] Group 2 - Saisir expects a net profit increase of 66.2% to 96.98% for the first half of 2025, driven by new product launches and improved sales [13] - WuXi AppTec anticipates a 44.43% increase in adjusted net profit for the first half of 2025, with revenue expected to reach approximately 20.799 billion yuan [15] - Yiyuan Communication forecasts a 121.13% increase in net profit for the first half of 2025, capitalizing on the growth of 5G and AI technologies [16] Group 3 - Longqing Co. expects a net profit increase of 106.02% to 131.77% for the first half of 2025, attributed to production capacity release and cost reduction [17] - Guosheng Financial Holdings predicts a net profit increase of 236.85% to 394.05% for the first half of 2025, supported by improved brokerage and investment banking performance [18] - Dali Long anticipates a net profit increase of 162.38% to 249.84% for the first half of 2025, driven by market expansion and operational efficiency [19] Group 4 - Tianbao Infrastructure expects a staggering net profit increase of 1581.8% to 2329.27% for the first half of 2025, largely due to a significant tax refund [20] - China Shipbuilding anticipates a net profit increase of 98.25% to 119.49% for the first half of 2025, benefiting from improved production efficiency and order structure [21] - Shanghai Xiba expects a net profit increase of 136.47% to 181.85% for the first half of 2025, influenced by non-recurring income [22] Group 5 - *ST Yanzhen reports a total of 53.773 million shares accepted in a tender offer, representing 20.47% of total equity, with a new major shareholder emerging [12] - Shanghai Mechanical and Electrical's major shareholder has received approval for a share transfer that will not change the company's control [10] - Good Products plans to suspend trading due to a potential change in control, with a suspension expected for no more than two trading days [11]

Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen markets have released important announcements, highlighting significant developments and performance forecasts that may impact investor decisions [1]. Company Announcements - **Saili Medical**: The therapeutic hypertension vaccine project by its affiliate, Huajiyuan Biotechnology, faces significant uncertainty despite recent market interest in innovative drugs. The company holds a 15.61% stake in Huajiyuan, which reported a revenue of 26,800 yuan and a net loss of 2,382,300 yuan for 2024 [3]. - **Renfu Pharmaceutical**: Shareholder,招商生科, has secured a loan commitment of up to 750 million yuan from招商银行武汉分行 to increase its stake in Renfu Pharmaceutical. The planned share buyback will occur within six months starting from July 3, 2025, with a maximum purchase price of 25.53 yuan per share [4]. - **China Merchants Energy Shipping**: The company has received a new multi-purpose heavy-lift vessel, "Mingshi," as part of its order for four eco-friendly vessels. The fleet now includes 102 operational bulk carriers, with 16 vessels on order for future delivery [5]. - **Shangwei New Materials**: The company announced a significant stock price fluctuation, with a 30% increase over two days. A share transfer agreement was signed, potentially changing the controlling shareholder to Zhiyuan Hengyue, pending shareholder approval [6]. - **Northern Rare Earth**: The trading price for rare earth concentrates has been adjusted to 19,109 yuan per ton for Q3 2025, based on market conditions [7]. - **Baotou Steel**: Similar to Northern Rare Earth, Baotou Steel has proposed an adjustment of the rare earth concentrate trading price to 19,109 yuan per ton for Q3 2025 [9]. - **Shanghai Mechanical & Electrical**: The company received approval from the Shanghai State-owned Assets Supervision and Administration Commission for the transfer of 51.137 million shares from its controlling shareholder, Shanghai Electric, without changing control [10]. Performance Forecasts - **Eyer Communication**: The company expects a net profit of approximately 463 million yuan for the first half of 2025, a year-on-year increase of about 121.13%, driven by growth in the IoT sector [12]. - **Tianbao Infrastructure**: The company forecasts a net profit of 90 million to 130 million yuan for the first half of 2025, representing a year-on-year increase of 1581.8% to 2329.27% due to tax recoveries [13]. - **China Shipbuilding**: The expected net profit for the first half of 2025 is between 2.8 billion and 3.1 billion yuan, reflecting a year-on-year increase of 98.25% to 119.49% due to improved production efficiency and order structure [14]. - **Shanghai Xiba**: The company anticipates a net profit of 99 million to 118 million yuan for the first half of 2025, a year-on-year increase of 136.47% to 181.85%, primarily due to non-recurring income [15]. - **Longyuan Technology**: The expected net profit for the first half of 2025 is between 26 million and 31 million yuan, reflecting a year-on-year increase of 116.61% to 158.26% [16]. - **Zhengbang Technology**: The company forecasts a net profit of 190 million to 210 million yuan for the first half of 2025, marking a return to profitability driven by increased pig sales [17][18]. - **Bolong Technology**: The expected net profit for the first half of 2025 is between 22 million and 28 million yuan, a year-on-year increase of 123.09% to 183.93% due to successful project deliveries [19]. - **Haitou Shares**: The company anticipates a net profit of approximately 380 million yuan for the first half of 2025, a year-on-year increase of about 233.10% due to favorable market conditions [20]. - **Chuangjiang New Materials**: The expected net profit for the first half of 2025 is between 24 million and 29 million yuan, reflecting a year-on-year increase of 42.35% to 72% [21]. - **Hudian Shares**: The company forecasts a net profit of between 1.65 billion and 1.75 billion yuan for the first half of 2025, a year-on-year increase of 44.63% to 53.4% [22]. - **Taiping Bird**: The company expects a net profit of around 77.7 million yuan for the first half of 2025, a decrease of approximately 55% due to declining retail performance [23]. - **China Satellite**: The company anticipates a loss of between 21.2 million and 41.2 million yuan for the first half of 2025, attributed to reduced contract fulfillment and increased operational costs [24]. - **ST Yatai**: The company expects a loss of between 12.6 million and 20.9 million yuan for the first half of 2025, primarily due to cash flow issues and increased non-recurring expenses [25]. Major Contracts - **Bai Da Group**: The company signed a significant leasing contract for the Hangzhou Department Store, with a rental agreement of 375 million yuan per quarter, increasing by 4.5% every three years [26]. Shareholding Changes - **Baoshui Technology**: A major shareholder plans to reduce their stake by up to 1% through market transactions between August 4 and November 3, 2025 [28].

Core Viewpoint - The financial advisor, China Merchants Securities Co., Ltd., has verified the detailed equity change report of Renfu Pharmaceutical Group Co., Ltd., confirming that the disclosed content and format comply with regulations and that there are no false records, misleading statements, or significant omissions [1][6][9]. Summary by Sections Financial Advisor's Verification - The financial advisor conducted a thorough review of the detailed equity change report and confirmed that the information provided by the disclosing party is true, accurate, complete, and timely, with no significant omissions or misleading statements [2][6]. - The advisor's opinion is based on the assumption that the disclosing party has fully and timely fulfilled its obligations related to the transaction [2][3]. Disclosing Party's Information - The disclosing party, China Merchants Life Science (Wuhan) Co., Ltd., has a registered capital of 200 million RMB and is involved in medical research and development [7][12]. - The equity structure of the disclosing party shows that it is wholly owned by China Merchants Innovation Technology (Group) Co., Ltd. [12][15]. Equity Change Details - Following the signing of the agreement, the disclosing party and its affiliates will collectively hold 429,276,816 shares of the listed company, accounting for 26.30% of the total share capital [5][9]. - The trust plan "Chun Ni 1" was established to execute the restructuring plan of the company "Wuhan Contemporary Technology Industry Group Co., Ltd." and involves the transfer of 11.70% of Renfu Pharmaceutical's shares [9][10]. Financial Performance of Related Entities - Wuhan High-Tech State-owned Holding Group Co., Ltd. reported total assets of 994.47 billion RMB, total liabilities of 707.50 billion RMB, and a net profit of 1.54 billion RMB for the year 2024 [23][24]. - The financial data for China Merchants Group shows total assets of 28,751.03 billion RMB and a net profit of 786.16 million RMB for the year 2024 [25].

Core Viewpoint - The report outlines the equity changes of Renfu Pharmaceutical Group Co., Ltd., detailing the involvement of various stakeholders and the establishment of a concerted action relationship between the parties involved to stabilize the company's management and promote its development [24][25]. Group 1: Equity Change Overview - The equity change involves the concerted action relationship established between招商生命科技 (Wuhan) Co., Ltd. and 武汉高科国有控股集团有限公司, allowing them to collectively hold 429,276,816 shares of Renfu Pharmaceutical, representing 26.30% of the total share capital [27][29]. - Prior to this change, the combined holdings of the involved parties were 403,089,608 shares, accounting for 24.70% of the total share capital [26][28]. Group 2: Stakeholder Information - 招商生命科技 holds 114,255,773 shares directly, equating to a 7.00% stake, while the other parties include 生科投资发展 with 97,933,558 shares (6.00%), 春泥 1号 with 190,900,277 shares (11.70%), and 武汉高科 with 26,187,208 shares (1.60%) [28]. - The report confirms that the stakeholders have not changed their respective shareholding percentages as a result of this equity change [27]. Group 3: Purpose and Future Plans - The primary purpose of this equity change is to stabilize the management of Renfu Pharmaceutical and enhance its governance structure, thereby improving asset quality and ensuring healthy development [25]. - 招商生科 plans to increase its holdings in Renfu Pharmaceutical by at least 1% and no more than 2% within six months following the announcement of the increase plan, with a maximum purchase price set at 25.53 RMB per share [25][26].

证券代码:600079 证券简称:人福医药 编号:临 2025-087 人福医药集团股份公司 关于股东增加一致行动人暨权益变动的提示性公告 特 别 提 示 重整服务信托（以下简称"春泥 1 号"）、武汉高科国有控股集团有限公司（以下简 称"武汉高科"）编制的《人福医药集团股份公司详式权益变动报告书》及招商生 科与武汉高科签署的《协议书》，招商生科与武汉高科双方达成在该《协议书》项 下的一致行动关系。 ● 本次权益变动前，招商生科、生科投资发展、春泥 1 号原已合计控制人福医 药 403,089,608 股股份、占公司总股本的 24.70%对应的表决权，截至本报告披露日， 因招商生科与武汉高科（持有公司 26,187,208 股股份，占公司总股本的 1.60%）签 署关于一致行动安排的《协议书》，合并计算招商生科、生科投资发展、春泥 1 号 及一致行动人武汉高科持股比例由 24.70%上升至 26.30%。本次权益变动未触及要 约收购。 ● 本次权益变动不触及控股股东和实际控制人发生变化。 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担 ...

人福医药集团股份公司 详式权益变动报告书 人福医药集团股份公司 详式权益变动报告书 上市公司名称：人福医药集团股份公司 股票上市地点：上海证券交易所 股票简称：人福医药 股票代码：600079 信息披露义务人一名称：招商生命科技（武汉）有限公司 住所及通讯地址：湖北省武汉市东湖新技术开发区九峰一路 1 号生物创新园二期 A12 栋 12-01 信息披露义务人二名称：招商生科投资发展（武汉）合伙企业（有限合伙） 住所及通讯地址：湖北省武汉市东湖新技术开发区九峰一路 1 号生物创新园二期 A12 栋 12-03 信息披露义务人三名称：中粮信托-春泥 1 号破产重整服务信托（由受益人招商生 命科技（武汉）有限公司代表披露） 信息披露义务人四名称：武汉高科国有控股集团有限公司 住所及通讯地址：武汉东湖新技术开发区高新大道 818 号武汉高科医疗器械园 B 地块三期 B14 栋 5 层 01 号 签署日期：二〇二五年七月十日 1 人福医药集团股份公司 详式权益变动报告书 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国公司法》《中华人民共 和国证券法》《上市公司收购管理办法》《公开发行证券的公司信息 ...

证券代码:600079 证券简称:人福医药 编号:临 2025-087 人福医药集团股份公司 关于股东增加一致行动人暨权益变动的提示性公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 重要内容提示 ● 人福医药集团股份公司（以下简称"人福医药"或"公司"）近日收到股东 招商生命科技（武汉）有限公司（以下简称"招商生科"）、招商生科投资发展（武 汉）合伙企业（有限合伙）（以下简称"生科投资发展"）、中粮信托-春泥 1 号破产 重整服务信托（以下简称"春泥 1 号"）、武汉高科国有控股集团有限公司（以下简 称"武汉高科"）编制的《人福医药集团股份公司详式权益变动报告书》及招商生 科与武汉高科签署的《协议书》，招商生科与武汉高科双方达成在该《协议书》项 下的一致行动关系。 ● 本次权益变动前，招商生科、生科投资发展、春泥 1 号原已合计控制人福医 药 403,089,608 股股份、占公司总股本的 24.70%对应的表决权，截至本报告披露日， 因招商生科与武汉高科（持有公司 26,187,208 股股份，占公司 ...